Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat hepatic impairment pharmacokinetics study in advanced solid tumors
NL-OMON34474Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of panobinostat in Nonhematologic neoplasms (4 arms), sponsored by Novartis. Primary endpoints: AUC0-t of panobinostat, AUC0-inf of panobinostat and 3 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
panobinostat
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON34474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34474.